Vaccines 2013, 1(4), 497-512; doi:10.3390/vaccines1040497

Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens

The Sir William Dunn School of Pathology, The University of Oxford, South Parks Road, Oxford OX13RE, UK
Received: 6 September 2013; in revised form: 11 October 2013 / Accepted: 12 October 2013 / Published: 28 October 2013
(This article belongs to the Special Issue HIV Vaccines)
PDF Full-text Download PDF Full-Text [580 KB, uploaded 28 October 2013 09:52 CET]
Abstract: The HIV-1 envelope glycoprotein spike is the target of neutralizing antibody attack, and hence represents the only relevant viral antigen for antibody-based vaccine design. Various approaches have been attempted to recapitulate Env in membrane-anchored and soluble forms, and these will be discussed here in the context of recent successes and challenges still to be overcome.
Keywords: HIV-1; vaccine; neutralizing antibodies; envelope glycoproteins; trimer

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Sattentau, Q.J. Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens. Vaccines 2013, 1, 497-512.

AMA Style

Sattentau QJ. Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens. Vaccines. 2013; 1(4):497-512.

Chicago/Turabian Style

Sattentau, Quentin J. 2013. "Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens." Vaccines 1, no. 4: 497-512.

Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert